Monogenic hypercholesterolemia: New insights in pathogenesis and treatment

Journal of Clinical Investigation

Volumn 111, Issue 12, 2003, Pages 1795-1803

  Rader, Daniel J ^a   Cohen, Jonathan ^b   Hobbs, Helen H ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADAPTOR PROTEIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NARC 1 PROTEIN; NEUTRAL APOPTOSIS REGULATED CONVERTASE 1; NICOTINIC ACID; PROTEINASE; RESIN; SITOSTEROL; STANOL ESTER; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN; SITOSTEROL DERIVATIVE;

ABCG5 GENE; ABCG8 GENE; APHERESIS; APOB GENE; ARH GENE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DIET RESTRICTION; ENZYME DEFICIENCY; ENZYME INHIBITION; FAMILIAL DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; LDLR GENE; LIPID BLOOD LEVEL; LOW FAT DIET; NONHUMAN; PATHOGENESIS; PCSK9 GENE; PRIORITY JOURNAL; REVIEW; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; DOMINANT GENE; GENETICS; HISTORY; HYPERLIPOPROTEINEMIA TYPE 2; METABOLISM; RECESSIVE GENE;

APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CORONARY ARTERIOSCLEROSIS; GENES, DOMINANT; GENES, RECESSIVE; HISTORY, 20TH CENTURY; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; SITOSTEROLS;

EID: 0041743167     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200318925     Document Type: Review

References (53)

1. Heller, D.A., de Faire, U., Pedersen, N.L., Dahlen, G., and McClearn, G.E. 1993. Genetic and environmental influences on serum lipid levels in twins. N. Engl. J. Med. 328:1150-1156
2. Goldstein, J., Hobbs, H., and Brown, M. 2001. Familial hypercholesterolemia. In The metabolic and molecular bases of inherited disease. C. Scriver, A. Beaudet, W. Sly, and D. Valle, editors. McGraw-Hill New York, New York, USA. 2863-2913.
3. Sun, X.M., et al. 1994. Familial hypercholesterelemia in China. Identification of mutations in the LDL-receptor gene that result in a receptor-negative phenotype. Arterioscler. Thromb. 14:85-94.
4. Hoeg, J.M., Feuerstein, I.M., and Tucker, E.E. 1994. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Atheroscler. Thromb. 14:1066-1074.
5. Hill, J.S., Hayden, M.R., Frohlich, J., and Pritchard, P.H. 1991. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler. Thromb. 11:290-297.
6. Rudenko, G., et al. 2002. Structure of the LDL receptor extracellular domain at endosomal pH. Science. 298:2353-2358.
7. Jeon, H., et al. 2001. Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. Nat. Struct. Biol. 8:499-504.
8. Horton, J.D., Shimano, H., Hamilton, R.L., Brown, M.S., and Goldstein, J.L. 1999. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Invest. 103:1067-1076.
9. Gillian-Daniel, D.L., Bates, P.W., Tebon, A., and Attie, A.D. 2002. Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc. Natl. Acad. Sci. U. S. A. 99:4337-4342.
10. The low density lipoprocein receptor (LDLR) gene in familial hyercholesterolemia. www.Ucl.ac.uk/fh.
11. Miettinen, T.A., and Gylling, H. 1999. Regulation of cholesterol metabolism by dietary plant sterols. Curr. Opin. Lipidol. 10:9-14.
12. Van Heek, M., et al. 1997. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor. SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J. Pharmacol. Exp. Ther. 283:157-163.
13. Gagne, C., Gaude, D., and Brucker, E. 2002. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 105:2469-2475.
14. Thompson, G.R. 2003. LDL apheresis. Atherosclerosis. 167:1-13.
15. Wetterau, J.R., et al. 1998. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science. 282:751-754.
16. Vega, G.L., and Grundy, S.M. 1986. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J. Clin. Invest. 78:1410-1414.
17. Soria, L.F., et al. 1989. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc. Natl. Acad. Sci. U. S. A. 86:587-591.
18. Myant, N.B. 1993. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 104:1-18.
19. Hansen, P.S. 1998. Familial defective apolipoprotein B-100. Dan. Med. Bull. 45:370-382.
20. Innerarity, T.L., et al. 1990. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J. Lipid Res. 31:1337-1349.
21. Schaefer, J.R., et al. 1997. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler Thromb. Vasc. Biol. 17:348-353.
22. Haddad, L., et al. 1999. Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred. J. Lipid. Res. 40:1113-1122.
23. Varret, M., et al. 1999. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am. J. Hum. Genet. 64:1378-1387.
24. Abifadel, M., et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. In press.
25. Seidah, N.G., et al. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A. 100:928-933.
26. Khachadurian, A.K., and Uthman, S.M. 1973. Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutr. Metab. 15:132-140.
27. Zuliani, G., et al. 1995. Severe hypercholesterolaemia: unusual inheritance in an Italian pedigree. Eur. J. Clin. Invest. 25:322-331.
28. Garcia, C.K., et al. 2001. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 292:1394-1398.
29. Cohen, J.C., Kimmel, M., Polanski, A., and Hobbs, H.H. 2003. Molecular mechanisms of autosomal recessive hypercholesterolemia. Curr. Opin. Lipidol. 14:121-127.
30. Eden, E.R., et al. 2002. Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1. J. Clin. Invest. 110:1695-1702. doi:10.1172/JCI200216445.
31. Norman, D., et al. 1999. Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholestetclemia. J. Clin. Invest. 104:619-628.
32. Forman-Kay J.D., and Pawson, T. 1999. Diversity in protein recognition by PTB domains. Curr. Opin. Struct. Biol. 9:690-695.
33. Davis, C.G., van Driel, I.R., Russell, D.W., Brown, M.S., and Goldstein, J.L. 1987. The low density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis. J. Biol. Chem. 262:4075-4082.
34. He, G., Gupta, S., Michaely, P., Hobbs, H.H., and Cohen, J.C. 2002. ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin and AP-2. J. Biol. Chem. 277:44044-44049.
35. Mishra, S.K., Watkins, S.C., and Traub, L.M. 2002. The autosomal recessive hypercholesterolemia (ARH) protein interfaces directly with the clathrin-coat machinery. Proc. Natl. Acad. Sci. U. S. A. 99:16009-16104.
36. Davis, C.G., et al. 1986. The J.D. mutation in familial hypercholesterolemia: amino acid substitution in cytoplasmic domain impedes internalization of LDL receptors. Cell. 45:15-24.
37. Gorthardt, M., et al. 2000. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J. Biol. Chem. 275:25616-25624.
38. Pathak, R.K., et al. 1990. Tissue-specific sorting of the human LDL receptor in polarized epithelia of transgenic mice. J. Cell Biol. 111:347-359.
39. Arca, M., et al. 2002. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet. 359:841-847.
40. Bhattacharyya, A.K., and Connor, W.E. 1974. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J. Clin. Invest. 53:1033-1043.
41. Salen, G., et al. 1992. Sitosterolemia. J. Lipid Res. 33:945-955.
42. Salen, G., Ahrens, E.H., Jr., and Grundy, S.M. 1970. Metabolism of beta-sitosterol in man. J. Clin. Invest. 49:952-967.
43. Berge, K.E., et al. 2000. Accumulation of dietary cholesterol in sito-sterolemia caused by mutations in adjacent ABC transporters. Science. 290:1771-1775.
44. Lee, M.H., et al. 2001. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat. Genet. 27:79-83.
45. Lu, K., et al. 2001. Two genes that map to the STSL locus cause sito-sterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am. J. Hum. Genet. 69:278-290.
46. Repa, J.J., et al. 2002. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277:18793-18800.
47. Yu, L., et al. 2002. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc. Natl. Acad. Sci. U. S. A. 99:16237-16242.
48. Salen, G., et al. 2002. Ezetimibe is an effective treatment for homozygous sitosterolemia. Circulation Supplement. 11-185.
49. Pullinger, C.R., et al. 2002. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin Invest. 110:109-117. doi:10.1172/JCI200215387.
50. Hobbs, H.H., Brown, M.S., Russell, D.W., Davignon, J., and Goldstein, J.L. 1987. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N. Engl. J. Med. 317:734-737.
51. Hegele, R.A. 2002. Environmental modulation of atherosclerosis end points in familial hypercholesterolemia. Atheroscler. Suppl. 2:5-7.
52. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:7-22.
53. Gylling, H., and Miettinen, T.A. 2002. Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis. 160:477-481.